These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33824166)

  • 1. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
    Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
    Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers.
    Odintsov I; Mattar MS; Lui AJW; Offin M; Kurzatkowski C; Delasos L; Khodos I; Asher M; Daly RM; Rekhtman N; de Stanchina E; Ganji G; Ladanyi M; Somwar R
    J Thorac Oncol; 2021 Jul; 16(7):1149-1165. PubMed ID: 33839363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
    Udagawa H; Nilsson MB; Robichaux JP; He J; Poteete A; Jiang H; Heeke S; Elamin YY; Shibata Y; Matsumoto S; Yoh K; Okazaki S; Masuko T; Odintsov I; Somwar R; Ladanyi M; Goto K; Heymach JV
    J Thorac Oncol; 2024 Jan; 19(1):106-118. PubMed ID: 37678511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.
    Garner AP; Bialucha CU; Sprague ER; Garrett JT; Sheng Q; Li S; Sineshchekova O; Saxena P; Sutton CR; Chen D; Chen Y; Wang H; Liang J; Das R; Mosher R; Gu J; Huang A; Haubst N; Zehetmeier C; Haberl M; Elis W; Kunz C; Heidt AB; Herlihy K; Murtie J; Schuller A; Arteaga CL; Sellers WR; Ettenberg SA
    Cancer Res; 2013 Oct; 73(19):6024-35. PubMed ID: 23928993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.
    Schram AM; Odintsov I; Espinosa-Cotton M; Khodos I; Sisso WJ; Mattar MS; Lui AJW; Vojnic M; Shameem SH; Chauhan T; Torrisi J; Ford J; O'Connor MN; Geuijen CAW; Schackmann RCJ; Lammerts van Bueren JJ; Wasserman E; de Stanchina E; O'Reilly EM; Ladanyi M; Drilon A; Somwar R
    Cancer Discov; 2022 May; 12(5):1233-1247. PubMed ID: 35135829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to ERBB3-Directed Targeted Therapy in
    Drilon A; Somwar R; Mangatt BP; Edgren H; Desmeules P; Ruusulehto A; Smith RS; Delasos L; Vojnic M; Plodkowski AJ; Sabari J; Ng K; Montecalvo J; Chang J; Tai H; Lockwood WW; Martinez V; Riely GJ; Rudin CM; Kris MG; Arcila ME; Matheny C; Benayed R; Rekhtman N; Ladanyi M; Ganji G
    Cancer Discov; 2018 Jun; 8(6):686-695. PubMed ID: 29610121
    [No Abstract]   [Full Text] [Related]  

  • 7. Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.
    Le Clorennec C; Bazin H; Dubreuil O; Larbouret C; Ogier C; Lazrek Y; Garambois V; Poul MA; Mondon P; Barret JM; Mathis G; Prost JF; Pèlegrin A; Chardès T
    Mol Cancer Ther; 2017 Jul; 16(7):1312-1323. PubMed ID: 28507002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
    Shin DH; Jo JY; Han JY
    Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.
    Ogier C; Colombo PE; Bousquet C; Canterel-Thouennon L; Sicard P; Garambois V; Thomas G; Gaborit N; Jarlier M; Pirot N; Pugnière M; Vie N; Gongora C; Martineau P; Robert B; Pèlegrin A; Chardès T; Larbouret C
    Cancer Lett; 2018 Sep; 432():227-236. PubMed ID: 29935372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis.
    Nagasaka M; Ou SI
    Trends Cancer; 2022 Mar; 8(3):242-258. PubMed ID: 34996744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.
    Curley MD; Sabnis GJ; Wille L; Adiwijaya BS; Garcia G; Moyo V; Kazi AA; Brodie A; MacBeath G
    Mol Cancer Ther; 2015 Nov; 14(11):2642-52. PubMed ID: 26310543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
    Yang L; Li Y; Shen E; Cao F; Li L; Li X; Wang X; Kariminia S; Chang B; Li H; Li Q
    Int J Oncol; 2017 Nov; 51(5):1553-1562. PubMed ID: 29048656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models.
    Meetze K; Vincent S; Tyler S; Mazsa EK; Delpero AR; Bottega S; McIntosh D; Nicoletti R; Winston WM; Weiler S; Feng B; Gyuris J; Weng Z
    Clin Cancer Res; 2015 Mar; 21(5):1106-14. PubMed ID: 25542901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
    Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
    Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring
    Kim DW; Schram AM; Hollebecque A; Nishino K; Macarulla T; Rha SY; Duruisseaux M; Liu SV; Al Hallak MN; Umemoto K; Wesseler C; Cleary JM; Springfeld C; Neuzillet C; Joe A; Jauhari S; Ford J; Goto K
    Future Oncol; 2024; 20(16):1057-1067. PubMed ID: 38348690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab.
    Orlova A; Bass TZ; Rinne SS; Leitao CD; Rosestedt M; Atterby C; Gudmundsdotter L; Frejd FY; Löfblom J; Tolmachev V; Ståhl S
    Mol Pharm; 2018 Aug; 15(8):3394-3403. PubMed ID: 29995421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
    Choi BK; Fan X; Deng H; Zhang N; An Z
    Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER3 Is an Actionable Target in Advanced Prostate Cancer.
    Gil V; Miranda S; Riisnaes R; Gurel B; D'Ambrosio M; Vasciaveo A; Crespo M; Ferreira A; Brina D; Troiani M; Sharp A; Sheehan B; Christova R; Seed G; Figueiredo I; Lambros M; Dolling D; Rekowski J; Alajati A; Clarke M; Pereira R; Flohr P; Fowler G; Boysen G; Sumanasuriya S; Bianchini D; Rescigno P; Aversa C; Tunariu N; Guo C; Paschalis A; Bertan C; Buroni L; Ning J; Carreira S; Workman P; Swain A; Califano A; Shen MM; Alimonti A; Neeb A; Welti J; Yuan W; de Bono J;
    Cancer Res; 2021 Dec; 81(24):6207-6218. PubMed ID: 34753775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung.
    Shin DH; Lee D; Hong DW; Hong SH; Hwang JA; Lee BI; You HJ; Lee GK; Kim IH; Lee YS; Han JY
    Oncotarget; 2016 Oct; 7(43):69450-69465. PubMed ID: 27626312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
    Razumienko EJ; Scollard DA; Reilly RM
    J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.